Spectral AI Announces Podium Presentation at BBA / ISBI Joint Conference Assessing Burn Wound Severity Using Multispectral Imaging and Artificial Intelligence
August 19 2024 - 8:00AM
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today announced that Dr. Jeffrey
Carter will present data from an ongoing prospective multicenter
study analyzing the use of Spectral AI’s DeepView™ System, which
utilizes non-invasive multispectral imaging technology and
proprietary AI, to detect non-healing areas of a wound following
thermal (burn) injury.
Dr. Carter is Medical Director of University
Medical Center New Orleans Burn Center & Professor of Surgery
at LSU Health New Orleans School of Medicine, and Spectral AI’s
Chief Medical Consultant.
Dr. Carter and his team note that burn care
resources in the U.S. are limited with only approximately 130 burn
centers, a tight supply of available burn center beds on any given
day, and a significant decline in burn surgeon training. These
constraints would be magnified in a mass casualty event and likely
result in inaccurate diagnoses and a diminished standard of
care.
Spectral AI’s DeepView™ System has a
demonstrated ability to accurately assess burn depth which exceeds
that of experienced physicians. This supports the Company’s belief
that a high performing AI-driven model using multi-spectral imaging
supplemented with clinician-based burn assessment is poised to
positively impact the speed, treatment and potential outcomes for
patients with acute burn wounds.
“The structural constraints in the ability of
our healthcare system to treat burn victims combined with the
complex nature of these wounds has resulted in significant
challenges for clinicians, patients, and institutions,” said Dr.
Carter. “We believe that Spectral AI’s DeepView™ System for burn
indication can address these care gaps by providing an immediate
and informed burn wound assessment with accuracy that far exceeds
that of even the most seasoned burn care physician. The predictive
ability of this technology can provide significant advantages
across the healthcare continuum on both a day-to-day basis and
during a mass casualty situation.”
Presentation Information
Presenter: Jeffrey E. Carter, MD,
FACSTitle: Burn Severity Assessment Using
Multispectral Imaging and AI: Analysis of a Multicenter Study
Day: Wednesday, August
21stTime: 15:30-17:00
BSTLocation: International Conference Centre
(ICC) Hall 11B, Birmingham, UK
The Company’s 2024 U.S. Burn Pivotal Study is
ongoing and is designed to validate the AI-driven algorithm used by
Spectral AI’s DeepView™ System for burn indication. It will be the
final clinical trial before the Company seeks FDA approval of its
DeepView™ System for burn indication in 2025.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive
AI company focused on medical diagnostics for faster and more
accurate treatment decisions in wound care, with initial
applications involving patients with burns and diabetic foot
ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView System.
The DeepView System is a predictive device that offers clinicians
an objective and immediate assessment of a wound’s healing
potential prior to treatment or other medical intervention. With
algorithm-driven results and a goal to change the current standard
of care, the DeepView System is expected to provide faster and more
accurate treatment insight towards value care by improving patient
outcomes and reducing healthcare costs. For more information about
the DeepView System, visit www.spectral-ai.com.
Forward Looking
Statements Certain statements made in this release
are “forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Investors: The Equity
Group Devin Sullivan Managing
Director dsullivan@equityny.com
Conor Rodriguez Analyst crodriguez@equityny.com
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
From Oct 2023 to Oct 2024